ES3063802T3 - Sulfopropanoic acid derivatives for treating neurodegenerative disorders - Google Patents
Sulfopropanoic acid derivatives for treating neurodegenerative disordersInfo
- Publication number
- ES3063802T3 ES3063802T3 ES23188362T ES23188362T ES3063802T3 ES 3063802 T3 ES3063802 T3 ES 3063802T3 ES 23188362 T ES23188362 T ES 23188362T ES 23188362 T ES23188362 T ES 23188362T ES 3063802 T3 ES3063802 T3 ES 3063802T3
- Authority
- ES
- Spain
- Prior art keywords
- acid derivatives
- neurodegenerative disorders
- treating neurodegenerative
- sulfopropanoic acid
- sulfopropanoic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/17—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing carboxyl groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/70—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a carbon skeleton substituted by carboxyl groups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
En el presente documento se describe el uso de un compuesto de fórmula I o una sal farmacéuticamente aceptable del mismo, para el tratamiento de una enfermedad caracterizada por agregados amiloides y similares a los amiloides, por ejemplo, la enfermedad de Alzheimer. (Traducción automática con Google Translate, sin valor legal)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713056P | 2018-08-01 | 2018-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3063802T3 true ES3063802T3 (en) | 2026-04-20 |
Family
ID=67587959
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19752609T Active ES2969887T3 (es) | 2018-08-01 | 2019-07-30 | Derivados de ácido sulfopropanoico para tratar trastornos neurodegenerativos |
| ES23188362T Active ES3063802T3 (en) | 2018-08-01 | 2019-07-30 | Sulfopropanoic acid derivatives for treating neurodegenerative disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19752609T Active ES2969887T3 (es) | 2018-08-01 | 2019-07-30 | Derivados de ácido sulfopropanoico para tratar trastornos neurodegenerativos |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US12285400B2 (es) |
| EP (3) | EP4296670B1 (es) |
| JP (1) | JP7466520B2 (es) |
| KR (2) | KR20260044262A (es) |
| CN (2) | CN112867487A (es) |
| AU (2) | AU2019314323B2 (es) |
| BR (1) | BR112021001718A2 (es) |
| CA (1) | CA3108182A1 (es) |
| DK (2) | DK3829568T3 (es) |
| EA (1) | EA202190359A1 (es) |
| ES (2) | ES2969887T3 (es) |
| FI (2) | FI3829568T3 (es) |
| HR (2) | HRP20231576T1 (es) |
| HU (1) | HUE064501T2 (es) |
| IL (2) | IL316611A (es) |
| LT (2) | LT4296670T (es) |
| MX (2) | MX2021001273A (es) |
| PL (2) | PL4296670T3 (es) |
| PT (2) | PT4296670T (es) |
| RS (2) | RS65022B1 (es) |
| SG (1) | SG11202100761PA (es) |
| SI (2) | SI4296670T1 (es) |
| SM (2) | SMT202300443T1 (es) |
| WO (1) | WO2020028348A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI4296670T1 (sl) | 2018-08-01 | 2026-04-30 | Alzheon, Inc. | Derivati sulfopropanojske kisline za zdravljenje nevrodegenerativnih motenj |
| CN114315655A (zh) * | 2021-12-18 | 2022-04-12 | 青岛科技大学 | 一种吸电子基团的不饱和烷烃的磺化方法 |
| CN120641092A (zh) | 2022-12-02 | 2025-09-12 | 阿尔泽恩股份有限公司 | 用于用曲米沙特治疗神经变性病症的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2440209A1 (de) * | 1974-08-22 | 1976-03-04 | Basf Ag | Beta-sulfo-propionsaeureverbindungen und verfahren zu ihrer herstellung |
| US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| US20020164368A1 (en) * | 2000-12-18 | 2002-11-07 | Ronald Zimmerman | Male contraceptive method and composition |
| CN1753662A (zh) * | 2002-12-24 | 2006-03-29 | 神经化学(国际)有限公司 | 用于治疗β-淀粉状蛋白相关疾病的治疗制剂 |
| AU2006321294A1 (en) * | 2005-09-30 | 2007-06-07 | Bellus Health (International) Limited | Pharmaceutical compositions comprising carboxyalkylsulfonic acids |
| WO2013024717A1 (ja) * | 2011-08-12 | 2013-02-21 | 宇部興産株式会社 | 非水電解液及びそれを用いた電気化学素子 |
| ES2960625T3 (es) | 2014-03-21 | 2024-03-05 | Alzheon Inc | Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+ |
| EP3347002B1 (en) | 2015-09-10 | 2023-06-07 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
| SI4296670T1 (sl) | 2018-08-01 | 2026-04-30 | Alzheon, Inc. | Derivati sulfopropanojske kisline za zdravljenje nevrodegenerativnih motenj |
-
2019
- 2019-07-30 SI SI201931024T patent/SI4296670T1/sl unknown
- 2019-07-30 KR KR1020267008754A patent/KR20260044262A/ko active Pending
- 2019-07-30 EA EA202190359A patent/EA202190359A1/ru unknown
- 2019-07-30 RS RS20231168A patent/RS65022B1/sr unknown
- 2019-07-30 CN CN201980064442.3A patent/CN112867487A/zh active Pending
- 2019-07-30 IL IL316611A patent/IL316611A/en unknown
- 2019-07-30 ES ES19752609T patent/ES2969887T3/es active Active
- 2019-07-30 EP EP23188362.0A patent/EP4296670B1/en active Active
- 2019-07-30 PL PL23188362.0T patent/PL4296670T3/pl unknown
- 2019-07-30 EP EP25210213.2A patent/EP4671757A3/en active Pending
- 2019-07-30 SI SI201930675T patent/SI3829568T1/sl unknown
- 2019-07-30 LT LTEP23188362.0T patent/LT4296670T/lt unknown
- 2019-07-30 DK DK19752609.8T patent/DK3829568T3/da active
- 2019-07-30 WO PCT/US2019/044114 patent/WO2020028348A1/en not_active Ceased
- 2019-07-30 KR KR1020217005804A patent/KR102944151B1/ko active Active
- 2019-07-30 BR BR112021001718-6A patent/BR112021001718A2/pt unknown
- 2019-07-30 RS RS20260213A patent/RS67770B1/sr unknown
- 2019-07-30 US US17/264,478 patent/US12285400B2/en active Active
- 2019-07-30 SG SG11202100761PA patent/SG11202100761PA/en unknown
- 2019-07-30 IL IL280441A patent/IL280441B2/en unknown
- 2019-07-30 HR HRP20231576TT patent/HRP20231576T1/hr unknown
- 2019-07-30 PL PL19752609.8T patent/PL3829568T3/pl unknown
- 2019-07-30 DK DK23188362.0T patent/DK4296670T3/da active
- 2019-07-30 PT PT231883620T patent/PT4296670T/pt unknown
- 2019-07-30 CN CN202511191099.2A patent/CN121045036A/zh active Pending
- 2019-07-30 PT PT197526098T patent/PT3829568T/pt unknown
- 2019-07-30 HR HRP20260248TT patent/HRP20260248T8/hr unknown
- 2019-07-30 SM SM20230443T patent/SMT202300443T1/it unknown
- 2019-07-30 JP JP2021505732A patent/JP7466520B2/ja active Active
- 2019-07-30 FI FIEP19752609.8T patent/FI3829568T3/fi active
- 2019-07-30 MX MX2021001273A patent/MX2021001273A/es unknown
- 2019-07-30 FI FIEP23188362.0T patent/FI4296670T3/fi active
- 2019-07-30 HU HUE19752609A patent/HUE064501T2/hu unknown
- 2019-07-30 CA CA3108182A patent/CA3108182A1/en active Pending
- 2019-07-30 SM SM20260077T patent/SMT202600077T1/it unknown
- 2019-07-30 ES ES23188362T patent/ES3063802T3/es active Active
- 2019-07-30 LT LTEPPCT/US2019/044114T patent/LT3829568T/lt unknown
- 2019-07-30 AU AU2019314323A patent/AU2019314323B2/en active Active
- 2019-07-30 EP EP19752609.8A patent/EP3829568B1/en active Active
-
2021
- 2021-01-29 MX MX2024013291A patent/MX2024013291A/es unknown
-
2025
- 2025-03-28 US US19/093,889 patent/US20260034088A1/en active Pending
- 2025-05-30 AU AU2025204068A patent/AU2025204068A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020001860A2 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| AR111693A1 (es) | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga | |
| CO2020006224A2 (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
| MX2019012445A (es) | Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. | |
| BR112021026445A2 (pt) | Composições e métodos para tratar distúrbios de cns | |
| BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
| MX2018008557A (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos. | |
| DOP2017000071A (es) | Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace. | |
| BR112022005674A2 (pt) | Derivado de anel fundido aromático substituído e composição compreendendo o mesmo, e uso do mesmo | |
| BR112021026462A2 (pt) | Composições e métodos para tratar distúrbios de cns | |
| MX2020003593A (es) | Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos. | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| CY1122290T1 (el) | Παραγωγο 2-ακυλαμινοθειαζολιου για χρηση στην προληψη ή αντιμετωπιση νοσων της ουροδοχου κυστης/του ουροποιητικου συστηματος | |
| PY1978496A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| MX2020008498A (es) | Derivados de sobetirome. | |
| BR112019007145A2 (pt) | combinação de um antagonista de pd-1 e eribulina para o tratamento de câncer urotelial | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| MX2019002369A (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial. | |
| EP3862012A4 (en) | THERAPEUTIC FOR NEURODEGENERATIVE DISEASES | |
| ES3063712T3 (en) | Compositions for treating neurodegenerative diseases | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| MX2024013291A (es) | Metodos para tratar trastornos neurodegenerativos |